Sensius is well on track with regards to the pre-commercial activities. It is successfully developing its sales pipeline. Relationship with leading research clinics intensified and new interested clinics showed interest to learn more about our solution. The first Letter Of Intent with Erasmus MC was signed. Next to developing the sales pipeline Sensius kicked off the landscaping of reimbursement in two of the target countries (The Netherlands and Germany) to develop a roadmap to ensure sufficient reimbursement in these markets.
Sensius is also setting up partnerships with local agents to act as its representatives and continuous to maintain relationships with strategic global partners to be able to accelerate sales when the time comes.
New technology development has also progressed. Multiple grants have been awarded to support Sensius with its future products. Sensius is the lead sponsor of the CARES project. It provides financial support and technology to enable neo-adjuvant chemotherapy dose escalation in the tumor to prevent mastectomy. This project strengthens Sensius’ position as a provider of a modular solution for thermotherapy for multiple body sites and facilitates any clinic’s decision on a positive business case, since more patients will be indicated for a thermotherapy treatment. In the RADIATHE project, Sensius, Technical University Eindhoven and Erasmus MC collaborate to develop improved instrumentations and workflows on quality assurance. These results will increase comfort and confidence at clinics on the administration of thermotherapy and thus lower any adoption threshold. And lastly, the SENS-TERM project aims to develop hardware and software for personalized, quality-controlled thermotherapy planning and treatment administration in H&N cancers, based on electromagnetic fields. The other project partners in SENS-THERM are Technical University Eindhoven, Erasmus University Medical Center Rotterdam and ZMT Zurich MedTech.
